This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.15% per year. These returns cover a period from January 1, 1988 through June 3, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
Zacks News
ICU Medical (ICUI) Beats Q4 Earnings Estimates
by Zacks Equity Research
ICU Medical (ICUI) delivered earnings and revenue surprises of 6.67% and 0.10%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?
Maravai LifeSciences Holdings, Inc. (MRVI) Tops Q4 Earnings Estimates
by Zacks Equity Research
Maravai LifeSciences Holdings, Inc. (MRVI) delivered earnings and revenue surprises of 2.94% and 0.30%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?
ICU Medical (ICUI) Stock Jumps 5.8%: Will It Continue to Soar?
by Zacks Equity Research
ICU Medical (ICUI) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
ICU Medical (ICUI) Surpasses Q3 Earnings and Revenue Estimates
by Zacks Equity Research
ICU Medical (ICUI) delivered earnings and revenue surprises of 24.11% and 6.21%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
Strength Seen in PetIQ (PETQ): Can Its 9.3% Jump Turn into More Strength?
by Zacks Equity Research
PetIQ (PETQ) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
New Strong Sell Stocks for September 8th
by Zacks Equity Research
CIEN, CYH and ICUI have been added to the Zacks Rank #5 (Strong Sell) List on September 8, 2022.
New Strong Sell Stocks for August 11th
by Zacks Equity Research
CBAN, ICUI, and NVDA have been added to the Zacks Rank #5 (Strong Sell) List on August 11, 2022.
ICU Medical (ICUI) Q2 Earnings and Revenues Lag Estimates
by Zacks Equity Research
ICU Medical (ICUI) delivered earnings and revenue surprises of -18.93% and 1.39%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
ICU Medical (ICUI) Surpasses Q1 Earnings Estimates
by Zacks Equity Research
ICU Medical (ICUI) delivered earnings and revenue surprises of 1.68% and 0.67%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
Zacks.com featured highlights include Meridian Bioscience, OP Bancorp, ICU Medical and Pangaea Logistics Solutions
by Zacks Equity Research
Meridian Bioscience, OP Bancorp, ICU Medical and Pangaea Logistics Solutions have been highlighted in this Screen of the Week article.
ICU Medical (ICUI) is a Great Momentum Stock: Should You Buy?
by Zacks Equity Research
Does ICU Medical (ICUI) have what it takes to be a top stock pick for momentum investors? Let's find out.
Is Hepion Pharmaceuticals, Inc. (HEPA) Stock Outpacing Its Medical Peers This Year?
by Zacks Equity Research
Here is how Hepion Pharmaceuticals, Inc. (HEPA) and ICU Medical (ICUI) have performed compared to their sector so far this year.
Buy These 4 Low-Beta Stocks to Combat the Choppy Market
by Nilanjan Banerjee
It is imperative to build a portfolio of low-beta stocks to sail through a choppy market. Meridian (VIVO), OP Bancorp (OPBK), ICU Medical (ICUI) and Pangaea Logistics (PANL) are well poised to gain.
Is ICU Medical (ICUI) a Solid Growth Stock? 3 Reasons to Think " Yes "
by Zacks Equity Research
ICU Medical (ICUI) possesses solid growth attributes, which could help it handily outperform the market.
Is Aptinyx Inc. (APTX) Outperforming Other Medical Stocks This Year?
by Zacks Equity Research
Here is how Aptinyx Inc. (APTX) and ICU Medical (ICUI) have performed compared to their sector so far this year.
Looking for a Growth Stock? 3 Reasons Why ICU Medical (ICUI) is a Solid Choice
by Zacks Equity Research
ICU Medical (ICUI) is well positioned to outperform the market, as it exhibits above-average growth in financials.
ICU Medical (ICUI) Surpasses Q4 Earnings and Revenue Estimates
by Zacks Equity Research
ICU Medical (ICUI) delivered earnings and revenue surprises of 11.66% and 6.30%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?
Analysts Estimate ICU Medical (ICUI) to Report a Decline in Earnings: What to Look Out for
by Zacks Equity Research
ICU Medical (ICUI) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Cardiovascular Systems (CSII) Reports Q2 Loss, Misses Revenue Estimates
by Zacks Equity Research
Cardiovascular Systems (CSII) delivered earnings and revenue surprises of -64.29% and 5.70%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?
3 Reasons Why ICU Medical (ICUI) Is a Great Growth Stock
by Zacks Equity Research
ICU Medical (ICUI) possesses solid growth attributes, which could help it handily outperform the market.
ICU Medical (ICUI) Q3 Earnings and Revenues Surpass Estimates
by Zacks Equity Research
ICU Medical (ICUI) delivered earnings and revenue surprises of 15.64% and 6.96%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?
Analysts Estimate ICU Medical (ICUI) to Report a Decline in Earnings: What to Look Out for
by Zacks Equity Research
ICU Medical (ICUI) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Company News for Sep 9, 2021
by Zacks Equity Research
Companies In The News Are: COIN, TSLA, SPB, ICUI
ICU Medical (ICUI) Q2 Earnings and Revenues Beat Estimates
by Zacks Equity Research
ICU Medical (ICUI) delivered earnings and revenue surprises of 14.63% and 5.02%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?
Earnings Preview: ICU Medical (ICUI) Q2 Earnings Expected to Decline
by Zacks Equity Research
ICU Medical (ICUI) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.